Repurposing Niclosamide for Targeting Pancreatic Cancer by Inhibiting Hh/Gli Non-Canonical Axis of Gsk3β

Repurposing Niclosamide for Targeting Pancreatic Cancer by Inhibiting Hh/Gli Non-Canonical Axis of Gsk3β

Niclosamide (Nic), an FDA-approved anthelmintic drug, is reported to have anti-cancer efficacy and is being assessed in clinical trials for various solid tumors. Based on its ability to target multiple signaling pathways, in the present study, we evaluated the therapeutic efficacy of Nic on pancreat...

Full description

Bibliographic Details
Main Authors: Jyoti B. Kaushal, Rakesh Bhatia, Ranjana K. Kanchan, Pratima Raut, Surya Mallapragada, Quan P. Ly, Surinder K. Batra, Satyanarayana Rachagani
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Cancers
Subjects:
niclosamide
pancreatic cancer
apoptosis
autophagy
Hh signaling
Gsk3β
Online Access:https://www.mdpi.com/2072-6694/13/13/3105

Internet

https://www.mdpi.com/2072-6694/13/13/3105

Similar Items